Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03491150 · ClinicalTrials.gov registry record · Phase 3
An Open-Label Crenezumab Study in Participants With Alzheimer's Disease
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 3
- Development phase
- 149
- Enrollment target
NCT03491150 is a Phase 3 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 149 participants.
The verdict
NCT03491150, a Phase 3 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 149 participants
- Enrollment target
Study Summary
In the BN40031 OLE study, a dose of crenezumab of 60 mg/kg intravenous (IV) every 4 weeks (Q4W) will be offered to all participants who complete Study BN29552 or BN29553 and who meet eligibility criteria in order to evaluate safety in participants on long-term crenezumab treatment and to investigate the effect of crenezumab on the underlying disease process and disease course as an exploratory efficacy objective.
Interventions
- DRUG Crenezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2018-04-11 |
| Est. Completion | 2019-05-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03491150
The ClinicalTrials.gov registry entry for NCT03491150 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Crenezumab is the first listed.
NCT03491150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03491150 about?
NCT03491150 is a clinical study titled "An Open-Label Crenezumab Study in Participants With Alzheimer's Disease". In the BN40031 OLE study, a dose of crenezumab of 60 mg/kg intravenous (IV) every 4 weeks (Q4W) will be offered to all participants who complete Study BN29552 or BN29553 and who meet eligibility criteria in order to evaluate safety in participants on long-term crenezumab treatment and to investigate...
What is the current status of trial NCT03491150?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 149 participants. The study started on 2018-04-11. Estimated completion is 2019-05-31.
What interventions are being tested in trial NCT03491150?
The interventions under investigation include: Crenezumab (DRUG).
Who is sponsoring clinical trial NCT03491150?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.